The Shift Toward De-escalation in Papillary Thyroid Microcarcinoma
For decades, the standard of care for papillary thyroid microcarcinoma (PTMC)—defined as papillary thyroid cancer measuring 1.0 cm or less—was immediate surgical intervention. However, the rising incidence of these low-risk lesions, often detected incidentally, has sparked a global debate regarding overdiagnosis and overtreatment. While the oncological prognosis for PTMC remains excellent regardless of the chosen intervention, the impact of treatment on a patient’s daily life has become a critical focal point for clinical decision-making. A landmark meta-analysis recently published in JAMA Otolaryngology–Head & Neck Surgery provides the most robust evidence to date that patient-reported outcomes (PROs) should play a central role in managing this condition.
